Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies
about
Matricellular proteins: a sticky affair with cancersThrombospondin-1 type 1 repeats in a model of inflammatory bowel disease: transcript profile and therapeutic effectsEndogenous thrombospondin-1 regulates leukocyte recruitment and activation and accelerates death from systemic candidiasisTherapeutic opportunities for targeting the ubiquitous cell surface receptor CD47Emerging functions of matricellular proteinsMatricellular protein CCN1 activates a proinflammatory genetic program in murine macrophagesMatrikine and matricellular regulators of EGF receptor signaling on cancer cell migration and invasionActivated CD47 regulates multiple vascular and stress responses: implications for acute kidney injury and its managementNeurexins and neuroligins: synapses look out of the nervous systemInhaled nitric oxide reduces endothelial activation and parasite accumulation in the brain, and enhances survival in experimental cerebral malariaMolecular basis of antiangiogenic thrombospondin-1 type 1 repeat domain interactions with CD36Cardiac CD47 drives left ventricular heart failure through Ca2+-CaMKII-regulated induction of HDAC3.Gene expression differences during the heterogeneous progression of peripheral atherosclerosis in familial hypercholesterolemic swine.Latexin Inactivation Enhances Survival and Long-Term Engraftment of Hematopoietic Stem Cells and Expands the Entire Hematopoietic System in Mice.Thalidomide attenuates nitric oxide-driven angiogenesis by interacting with soluble guanylyl cyclase.A combinatorial approach for targeted delivery using small molecules and reversible masking to bypass nonspecific uptake in vivoCD47 deficiency in tumor stroma promotes tumor progression by enhancing angiogenesis.Thrombospondin-1 activation of signal-regulatory protein-α stimulates reactive oxygen species production and promotes renal ischemia reperfusion injury.A role for thrombospondin-1 deficits in astrocyte-mediated spine and synaptic pathology in Down's syndrome.Targeting the vasculature in hepatocellular carcinoma treatment: Starving versus normalizing blood supply.Homocysteine disrupts outgrowth of microvascular endothelium by an iNOS-dependent mechanismA hypothesis on biological protection from space radiation through the use of new therapeutic gases as medical counter measures.Cross-platform array screening identifies COL1A2, THBS1, TNFRSF10D and UCHL1 as genes frequently silenced by methylation in melanoma.CD47 signaling regulates the immunosuppressive activity of VEGF in T cells.Blockade of CD47 increases survival of mice exposed to lethal total body irradiationThrombospondin-1 inhibits VEGF receptor-2 signaling by disrupting its association with CD47.Host deficiency in caveolin-2 inhibits lung carcinoma tumor growth by impairing tumor angiogenesis.CD47 in the tumor microenvironment limits cooperation between antitumor T-cell immunity and radiotherapyHeparan sulfate modification of the transmembrane receptor CD47 is necessary for inhibition of T cell receptor signaling by thrombospondin-1.sFRP-1 binds via its netrin-related motif to the N-module of thrombospondin-1 and blocks thrombospondin-1 stimulation of MDA-MB-231 breast carcinoma cell adhesion and migration.Effect and mechanism of thrombospondin-1 on the angiogenesis potential in human endothelial progenitor cells: an in vitro studyThrombospondin-1: multiple paths to inflammation.Six degrees of separation: the oxygen effect in the development of radiosensitizers.The thrombospondins.Clinical status and cardiovascular risk profile of adults with a history of juvenile dermatomyositis.Thrombospondin-1 regulates bone homeostasis through effects on bone matrix integrity and nitric oxide signaling in osteoclastsThrombospondin-1 induction in the diabetic myocardium stabilizes the cardiac matrix in addition to promoting vascular rarefaction through angiopoietin-2 upregulation.Matricellular proteins in cardiac adaptation and disease.Therapeutic targeting of the thrombospondin-1 receptor CD47 to treat liver cancer.Endothelial nitric oxide synthase controls the expression of the angiogenesis inhibitor thrombospondin 2
P2860
Q21296660-9F6BED3B-E9D3-4627-80CC-E8C86AA7F085Q21561021-88727BB9-EC5F-4D54-8049-86A566D31D7AQ24303620-14D49E77-DA8C-4667-92DF-431AFDC32031Q24627155-E5955A77-C70E-4833-868A-700E678C4B52Q24630445-02CE1C46-DB3D-4084-8C3A-AD2F3B808979Q24633369-A9EF66D4-EFFF-40AC-BBBC-EC81BFFA9382Q26824518-7DA3125D-FD47-460F-8C5D-74A8A34B1F3EQ26864499-1B655EEB-D1D2-4BDB-8C39-BC7F2EC75354Q28307076-25AC79D3-F7CC-4F93-BF93-99DC2CF076BDQ28742640-94557CA4-A2DF-449D-8088-818C0A7105EEQ29147397-9F1B344E-1329-48EA-A37A-D09574EC4A8BQ30618651-AA51202C-0073-4E98-ACC8-047E3D496112Q31122524-4DE43795-4E6E-4A8C-8EB5-861B300D1A38Q33559651-55A3CF94-BE8E-459D-9143-651D523A187FQ33569519-5B49177D-A73E-4F08-9187-254E31E0CC9BQ33576606-CF7B0026-856F-4876-8B86-206088ABA134Q33618348-3C19518A-73A1-4457-AF7A-2D8CBB9C9045Q33660552-BB0F6137-3081-4D69-BB27-8F20E95455E6Q33769845-801377EB-0BA6-4310-8CB4-7F8F33EC509CQ33920350-D5BE7475-7A82-4CE5-8701-DC1623CD0FD7Q34021054-25352BE4-EB57-4D77-BB3B-E22EEB47B48FQ34031361-1BAA0252-19A4-4FE8-83E6-324FACD74209Q34058385-68D133D1-B95D-4D47-BB6B-C58544FC2AF4Q34289358-48C77D05-D152-4B27-AE04-BF265EBBA126Q34321730-779BD36C-4468-422F-9A6D-A0CD4BB1D106Q34385843-71CBA97C-DF39-47E8-8264-64C3A826998CQ34518452-57C902C0-C1C0-448B-984C-7D3BFD840021Q34621578-5B43D707-9D88-4DAA-B5C5-003D7B8F584CQ34869450-C3E3A141-AA2C-4EC6-B5DF-F933E5329E54Q34904445-76F1E406-B013-4909-9F8A-283F66440A81Q35088607-363E0FF0-9272-4AF6-A1D1-1C5990D38FDEQ35098885-652CB361-7FC6-471E-868D-D1EEDA6F9652Q35116798-4790DE5A-4646-4FF7-B7C4-34DD662F207AQ35230013-27326B65-E814-4346-AE52-DD1550431067Q35349884-62C91E48-B555-491E-A92A-AA9516A002D3Q35493987-4752B7FE-EFBA-4F6D-BB11-B0BB0BAC9A46Q35534242-A141B26E-C62E-4268-B777-A65270DBDC77Q35542423-9199FF36-D72F-4C03-979D-54673156B092Q35554493-459BFBA7-CE38-496B-A98A-307D71F75EDCQ35558854-9AFC8652-6E49-4C01-8466-D17861A5E934
P2860
Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 05 February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Regulation of nitric oxide sig ...... for anti-angiogenic therapies
@en
Regulation of nitric oxide sig ...... for anti-angiogenic therapies.
@nl
type
label
Regulation of nitric oxide sig ...... for anti-angiogenic therapies
@en
Regulation of nitric oxide sig ...... for anti-angiogenic therapies.
@nl
prefLabel
Regulation of nitric oxide sig ...... for anti-angiogenic therapies
@en
Regulation of nitric oxide sig ...... for anti-angiogenic therapies.
@nl
P2093
P2860
P356
P1476
Regulation of nitric oxide sig ...... for anti-angiogenic therapies
@en
P2093
Gema Martin-Manso
Jeff S Isenberg
Justin B Maxhimer
P2860
P2888
P304
P356
10.1038/NRC2561
P407
P577
2009-02-05T00:00:00Z